Press release
Pulmonary Sarcoidosis Pipeline Insights, Clinical Trials, Emerging Drugs and Companies 2024
Discover the latest drugs and treatment options in the Pulmonary Sarcoidosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Sarcoidosis Pipeline Outlook [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Pulmonary Sarcoidosis Pipeline Report
* In October 2024:- Kinevant Sciences GmbH- A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis. Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.
* In September 2024:- Xentria Inc.- A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations. A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
* In September 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
* DelveInsight's Pulmonary Sarcoidosis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Pulmonary Sarcoidosis treatment.
* The leading Pulmonary Sarcoidosis Companies such as Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA , and others.
* Promising Pulmonary Sarcoidosis Therapies such as BMS-986278, Inhaled Treprostinil, Namilumab , and others
Stay ahead with the most recent pipeline outlook for Pulmonary Sarcoidosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Sarcoidosis Treatment Drugs [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Sarcoidosis Emerging Drugs
* CMK 389: Novartis
CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.
* ATYR1923: aTyr Pharma
ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.
Explore groundbreaking therapies and clinical trials in the Pulmonary Sarcoidosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Sarcoidosis Drugs [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravaginal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
Pulmonary Sarcoidosis Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
Unveil the future of Pulmonary Sarcoidosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Sarcoidosis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pulmonary Sarcoidosis Pipeline Report
* Coverage- Global
* Pulmonary Sarcoidosis Companies- Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others.
* Pulmonary Sarcoidosis Therapies- BMS-986278, Inhaled Treprostinil, Namilumab, and others.
* Pulmonary Sarcoidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pulmonary Sarcoidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Pulmonary Sarcoidosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Sarcoidosis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Pulmonary Sarcoidosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pulmonary Sarcoidosis- DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Pulmonary Sarcoidosis Collaboration Deals
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CMK389: Novartis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* ATYR1923: aTyr Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* LAM-001: AI Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pulmonary Sarcoidosis Key Companies
* Pulmonary Sarcoidosis Key Products
* Pulmonary Sarcoidosis- Unmet Needs
* Pulmonary Sarcoidosis- Market Drivers and Barriers
* Pulmonary Sarcoidosis- Future Perspectives and Conclusion
* Pulmonary Sarcoidosis Analyst Views
* Pulmonary Sarcoidosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-sarcoidosis-pipeline-insights-clinical-trials-emerging-drugs-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Sarcoidosis Pipeline Insights, Clinical Trials, Emerging Drugs and Companies 2024 here
News-ID: 3681110 • Views: …
More Releases from ABNewswire
Chronic Lower Back Pain Pipeline 2025: Latest FDA Approvals, Clinical Trials, an …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Lower Back Pain pipeline constitutes 10+ key companies continuously working towards developing 10+ Chronic Lower Back Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Lower Back Pain Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-lower-back-pain-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic…
Che Vita Makes Holiday Entertaining Effortless with Exclusive Rewards for Large …
Celebrate the season with curated menus, private event spaces, and exclusive rewards
Tampa, FL - This holiday season, Che Vita [https://www.chevitatampa.com/], the Italian-inspired dining destination located inside Hilton Tampa Downtown [https://www.hilton.com/en/hotels/tpanthf-hilton-tampa-downtown/], is making it easier than ever to celebrate in style. Guests who book their holiday or large parties by October 31, 2025, for events taking place between November 15, 2025, and January 15, 2026, will receive 25,000 Hilton Honors Points…
Chef-Driven Coffee Shop, Southern Grounds, Officially Opens in St.Petersburg, FL
St. Petersburg, Fla. - September 17th, 2025 - Southern Grounds [https://www.southerngrounds.com/] is thrilled to announce the opening of its new location in St. Petersburg, Florida. Originally founded in Jacksonville, Southern Grounds aims to establish itself in St. Pete as a community hub offering high-quality coffee, food, ambiance, and hospitality.
The Mission
Southern Grounds is a chef-driven coffee shop providing sustainably sourced food and beverages. The brand's mission is to "Nourish, nurture and…
Groundbreaking Auburn University Research Reveals Key Advances in Managing Felin …
Auburn University Research Advancing Feline Obesity Management Funded by EveryCatHealth Foundation, Nestle Research and Auburn University's Intramural Grant Program and Scott-Ritchey Research Center
Wyckoff, New Jersey - A groundbreaking study conducted by Auburn University's College of Veterinary Medicine [https://www.vetmed.auburn.edu/], funded in part by EveryCat Health Foundation [https://everycat.org/], the world's only nonprofit focused solely on feline health research internationally, and a cadre of leading feline health grant organizations, has released study results…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
